India is deliberating a string of initiatives to ensure that drugs for rare diseases reach patients faster and are available at "reasonable" prices in the country.
The US, EU and Japan, among others, have specific legislation to encourage research of rare diseases and the development of orphan drugs, and India's efforts to consider various incentives appear to be early steps towards this direction.
India's plans also come in the backdrop of a 2014 court order against the Government of the national capital territory of Delhi where the court noted how the lack of...
Despite new challenges related to obesity drug insurance coverage in the US, MetaVia's CEO is confident in the company's novel contender, which unlike rival GLP-1 therapies doesn’t require dose titration.
Expert panel including Ashok Venkitaraman, director of the Cancer Science Institute of Singapore, discusses public health challenges and innovations to help address these. Long-acting drugs, intercepting cancer early and “design thinking” by ophthalmologists in India were among the talking points.
Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now
South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.
Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.
Data from AstraZeneca/Daiichi’s breast cancer trial showed positive PFS, but some oncologists are waiting for confirmation of statistically significant OS benefit.
But the French major is still keen on early-stage M&A.
